Update on the treatment of patients with non-genotype 1 hepatitis C virus infection (Q27000806)

Leonardo Mottola

series ordinal

2

1 reference

Valeria Piazzolla

series ordinal

3

1 reference

language of work or name

1 reference

May 2013

1 reference

Clinical Infectious Diseases

published in

1 reference

volume

56

1 reference

issue

9

1 reference

page(s)

1294-300

1 reference

A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel

cites work

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS1195

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS1195

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS1195

Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS1195

Reduced dose and duration of peginterferon alfa-2b and weight-based ribavirin in patients with genotype 2 and 3 chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS1195

The prevalence of hepatitis C virus infection in the United States, 1988 through 1994

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS1195

Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS1195

Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS1195

Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS1195

A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS1195

Short versus standard treatment with pegylated interferon alfa-2A plus ribavirin in patients with hepatitis C virus genotype 2 or 3: the cleo trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS1195

Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS1195

Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS1195

Identifying hepatitis C virus genotype 2/3 patients who can receive a 16-week abbreviated course of peginterferon alfa-2a (40KD) plus ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS1195

An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS1195

EASL Clinical Practice Guidelines: management of hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS1195

Response-guided peg-interferon plus ribavirin treatment duration in chronic hepatitis C: meta-analyses of randomized, controlled trials and implications for the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS1195

Determinants of relapse after a short (12 weeks) course of antiviral therapy and re-treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS1195

Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS1195

Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS1195

Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS1195

An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS1195

Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS1195

Interleukin 28B gene variation at rs12979860 determines early viral kinetics during treatment in patients carrying genotypes 2 or 3 of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS1195

Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon alfa-2a and ribavirin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS1195

IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS1195

Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS1195

HCV infection and metabolic syndrome: which is the chicken and which is the egg?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS1195

Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS1195

Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS1195

Individualized treatment with combination of Peg-interferon alpha 2b and ribavirin in patients infected with HCV genotype 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS1195

Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS1195

Management of hepatitis C virus genotype 4: recommendations of an international expert panel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS1195

Resistance to mericitabine, a nucleoside analogue inhibitor of HCV RNA-dependent RNA polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS1195

Peginterferon-α-2a (40KD) and Ribavirin for 16 or 24 Weeks in Patients With Genotype 2 or 3 Chronic Hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS1195

21 January 2018

Identifiers

DOI

10.1093/CID/CIS1195

0 references

PubMed publication ID

23271787

1 reference